KRAS and non-small cell lung carcinoma: Based on synthetic lethality, NCT02079740 is a phase Ib/II trial investigating safety and tolerability of the combination of the BCL inhibitor navitoclax and trametinib, while NCT03095612 is a phase I/II trial evaluating selinexor, an inhibitor of exportin-1 (XPO1), in combination with docetaxel in previously treated KRAS mutant NSCLC.